Fig. 2.

Survival benefit of RRV gene therapy in intracranial glioma models. (A) U-87 model. Toca 511+5-FC showed significantly increased survival compared with control groups (87.5% survival for >120 days; P < .0001). Shaded areas: daily 5-FC cycles. (B–D) Tu-2449 models. (B) Low dose: 1.6 × 10⁴ TU. Daily 5-FC was commenced continuously on day 10 for either 14 or 21 consecutive days (Toca 511+5-FC × 14 or 21). Toca 511+5-FC showed significantly increased survival compared with Toca 511+PBS (40% survival for >240 days; P < .005). Hatched area: daily 5-FC × 14 days, shaded area: daily 5-FC × 21 days. (C) High dose: 3 × 10⁶ TU. Twice-daily 5-FC was commenced on day 10 for 4 consecutive days at 2-week intervals (Toca 511+5-FC). Toca 511+5-FC showed significantly increased survival compared with Toca 511+PBS (82% survival for >160 days; P < .0001). Gray areas: twice-daily 5-FC cycles. (D) High dose: 2 × 10⁶ TU. Daily 5-FC was commenced on day 10 for 7 consecutive days at 10-day intervals (Toca 511+5-FC). Toca 511+5-FC showed significantly increased survival compared with control groups (100% survival for >300 days; P < .0001). Gray areas: daily 5-FC cycles.